Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

05 Mar 2017 - 09 Mar 2017
20 Mar 2017 - 23 Mar 2017
12 Apr 2017 - 14 Apr 2017

LGC Acquires Bioanalytical Sciences from Quotient Bioresearch

By BiotechDaily International staff writers
Posted on 14 Jan 2013
ADVERTISEMENT
SARTORIUS AG
LGC (London, UK) and Quotient Bioresearch (Fordham, Cambridgeshire, UK) have announced an agreement on the sale by Quotient Bioresearch of its Bioanalytical Sciences division to LGC.

Quotient’s Bioanalytical Sciences is a leading provider of bioanalytical services across the fields of small molecules, biomarkers, biopharmaceuticals, and microbiological testing to customers in the pharmaceutical and biotechnology sectors. Upon acquisition, the Bioanalytical division will form part of LGC’s Health Sciences division and will enable LGC to provide an enhanced range of products and services to the pharmaceutical sector, including bioanalysis, materials science, and reference materials, amongst others.


Under the terms of the transaction, Quotient and LGC have committed to collaborate as preferred partners on the provision of Bioanalytical Sciences. This will enable clients to continue to benefit from the early development services offered by the Quotient group, including clinical trials, metabolism, and radiolabelling. For the time being, the Bioanalytical Sciences business will continue to trade using the “Quotient” name under its new ownership. The transaction follows the sale two years ago by Quotient to LGC of HFL Sport Science.


“We’re delighted to have acquired Quotient Bioanalytical Sciences, a high quality business which is complementary to our existing activities. We continue to develop our range of first-rate services in the pharmaceutical, biotechnology and agrochemical sectors by offering our customers a unique mix of technical experience, leading edge facilities and knowledgeable people,” said Jeremy Cook, managing director of LGC’s Health Sciences. Dr. Steve Pleasance, managing director of Quotient Bioanalytical Sciences said, “LGC’s focus on complex analytical chemistry, high quality science and service delivery make them a natural home for our business. Both our organizations have reputations built upon quality and innovation and LGC’s global presence will help support the continued growth of services to our customers.”

Related Links:

LGC
Quotient Bioresearch



Channels

Drug Discovery

view channel
Image: The experimental drug NGI-1 slows cancer growth by blocking glycosylation of the epidermal growth factor receptor (EGFR), which is shown in the above diagram (Photo courtesy of Wikimedia Commons).

Experimental Drug Slows Lung Cancer Growth by Blocking Protein Glycosylation

An interesting new experimental anti-cancer drug slows growth of certain lung tumor cells by preventing the glycosylation of critical cell surface receptor proteins. Asparagine (N)-linked glycosylation... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.